Clinical Trials Logo

Encephalitis, Japanese clinical trials

View clinical trials related to Encephalitis, Japanese.

Filter by:

NCT ID: NCT00314145 Completed - Clinical trials for Japanese Encephalitis

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVaxTM-JE and JE-VAX to the respective homologous virus strain after completion of vaccination course.

NCT ID: NCT00314132 Completed - Clinical trials for Japanese Encephalitis

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess whether ChimeriVax™ JE vaccine (a new vaccine to be used for vaccination against Japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.

NCT ID: NCT00249769 Completed - Clinical trials for Encephalitis, Japanese B

Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine

Start date: November 21, 2005
Phase: Phase 3
Study type: Interventional

This study will determine whether it is safe and effective to administer Japanese encephalitis (JE) live attenuated SA 14-14-2 vaccine at the same time as measles vaccine. If it is found to be safe, it will pave the way for use in routine vaccination programs. The hypothesis is that children who receive JE live attenuated SA 14-14-2 vaccine and measles vaccine at the same time are protected against these diseases at the same level as those who receive the vaccines at different intervals.

NCT ID: NCT00216268 Recruiting - Clinical trials for Japanese Encephalitis

Treatment of Japanese Encephalitis

Start date: July 2005
Phase: Phase 2
Study type: Interventional

Japanese encephalitis is the single largest cause of viral encephalitis in the world today. It occurs in yearly post monsoon outbreaks in Uttar Pradesh and other parts of India and south east Asia. There is presently no antiviral drug of proven benefit for this illness and treatment is mostly supportive. The drug Ribavirin is already in the market in use for other indications. It has been found useful in West Nile encephalitis and various hemorrhagic fevers caused by related arboviruses. This is a double blind placebo of Ribavirin in Japanese encephalitis. To the best of our knowledge, this is the first such trial in the world. The study hypothesis is that children treated with ribavirin will be no different from those getting placebo in terms of mortality, length of hospital stay, days to return to consciousness and oral feeds, days to become afebrile and convulsion free and in 3 month sequelae rate.